Search Results

STRM.BIO announced the continuation of their grant from the Bill & Melinda Gates Foundation to create novel technology platform capabilities for in vivo delivery of gene therapies being developed by the foundation.

STRM.BIO today announced the appointment of Minnie Mildwoff, to its Board of Directors.

STRM.BIO today announced the appointment of Dawn Bell , PharmD, to its Board of Directors.

STRM.BIO presented the first preclinical data on their novel delivery platform that uses megakaryocyte-derived EVs to target hematopoietic stem/progenitor cells (HSPCs) in the bone marrow at the American Society of Hematology (ASH) annual meeting being held in San Diego, California, December 9 – 12, 2023.

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

STRM.BIO announced that it will present preclinical data on their novel delivery platform for in vivo gene therapy that uses megakaryocyte-derived EVs to target hematopoietic stem cells in the bone marrow at the 65th American Society of Hematology Annual Meeting being held in San Diego, California, December 9 – 12, 2023.

STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles to deliver gene therapies and developing new therapeutics for rare blood diseases, announced that CEO Jonathan Thon, Ph.D. is the featured speaker at the 5th annual R. D. Zeigler Innovation Research Lecture Sponsored by the Versiti Blood Research Institute.

STRM.BIO presented the first preclinical data on the company’s novel delivery platform for in vivo gene therapy that uses megakaryocyte-derived EVs to target bone marrow hematopoietic stem cells at the 2023 Cell & Gene Meeting on the Mesa being held in Carlsbad, California.

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.